HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

American Safety Razor

This article was originally published in The Rose Sheet

Executive Summary

Acquired by J.W. Childs Equity Partners II, the firm announced Feb. 15. Under the definitive merger deal, the investment firm agrees to purchase American Safety Razor for approximately $173 mil. in cash, or $14 1/8 per share. American Safety Razor's board unanimously approved the deal. Funding is provided by $245 mil. of debt commitments by J.W. Childs, NationsBank and Donaldson, Lufkin & Jenrette. J.W. Childs has also made an equity investment commitment of $90 mil. PaineWebber represented American Safety; the investment firm was brought on in 1998 to explore the manufacturer's strategic options ("The Rose Sheet" Feb. 9, 1998, In Brief). American Safety Razor markets Revlon Perfect Finish female shave system and the Burma Shave, Flicker, Bump Fighter and LegMate brands

You may also be interested in...



American SafetyTri-Flexxx Triple-Blade Infringes Mach3 Patents - Suit

American Safety Razor has "violated" Gillette's Mach3 shaving system patents with the introduction of the Verona, Va.-based company's Tri-Flexxx triple-blade razor, Gillette asserted June 29.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel